Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study.

IF 1.7 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

European Journal of Hybrid Imaging Pub Date : 2021-12-09 DOI:10.1186/s41824-021-00116-z

Sander C Ebbers, Muriël Heimgartner, Maarten W Barentsz, Rachel S van Leeuwaarde, Mark J C van Treijen, Marnix M E G Lam, Arthur J A T Braat

{"title":"Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study.","authors":"Sander C Ebbers, Muriël Heimgartner, Maarten W Barentsz, Rachel S van Leeuwaarde, Mark J C van Treijen, Marnix M E G Lam, Arthur J A T Braat","doi":"10.1186/s41824-021-00116-z","DOIUrl":null,"url":null,"abstract":"Background: Early [68Ga]Ga-DOTA-TOC PET/CT imaging after peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasm patients is often used as a prognosticator for survival, but lacks validity. This study investigates the prognostic value of changes in PET parameters after PRRT.Methods: Baseline and follow-up [68Ga]Ga-DOTA-TOC PET/CT scans of all patients treated with PRRT were delineated automatically. Total lesion somatostatin receptor expression (TL-SSTR) and somatostatin receptor expressing tumor volume (SSTR-TV) were used as covariates in Cox proportional hazard models to predict time-to-new treatment.Results: In twenty patients, median time-to-new treatment was 19.3 months (range [3.8; 36.2]). Absolute and percentual changes in both PET parameters were not associated with time-to-new treatment. A significant relation between independent baseline and follow-up SSTR-TV and follow-up TL-SSTR, and time-to-new treatment was identified.Conclusions: Automatically derived [68Ga]Ga-DOTA-TOC PET/CT parameters are easy to acquire and may be of prognostic value after completing PRRT. Acquiring SSTR-TV or TL-SSTR parameters at baseline and during follow-up can be of value in identifying a patient's prognosis.","PeriodicalId":36160,"journal":{"name":"European Journal of Hybrid Imaging","volume":"5 1","pages":"22"},"PeriodicalIF":1.7000,"publicationDate":"2021-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655066/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Hybrid Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41824-021-00116-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Early [⁶⁸Ga]Ga-DOTA-TOC PET/CT imaging after peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasm patients is often used as a prognosticator for survival, but lacks validity. This study investigates the prognostic value of changes in PET parameters after PRRT.

Methods: Baseline and follow-up [⁶⁸Ga]Ga-DOTA-TOC PET/CT scans of all patients treated with PRRT were delineated automatically. Total lesion somatostatin receptor expression (TL-SSTR) and somatostatin receptor expressing tumor volume (SSTR-TV) were used as covariates in Cox proportional hazard models to predict time-to-new treatment.

Results: In twenty patients, median time-to-new treatment was 19.3 months (range [3.8; 36.2]). Absolute and percentual changes in both PET parameters were not associated with time-to-new treatment. A significant relation between independent baseline and follow-up SSTR-TV and follow-up TL-SSTR, and time-to-new treatment was identified.

Conclusions: Automatically derived [⁶⁸Ga]Ga-DOTA-TOC PET/CT parameters are easy to acquire and may be of prognostic value after completing PRRT. Acquiring SSTR-TV or TL-SSTR parameters at baseline and during follow-up can be of value in identifying a patient's prognosis.

Abstract Image

查看原文本刊更多论文

镓68-生长抑素受体PET/CT参数作为肽受体放射性核素治疗后临床进展时间的潜在预测因素：一项队列研究。

背景:神经内分泌肿瘤患者肽受体放射性核素治疗(PRRT)后早期[68Ga]Ga-DOTA-TOC PET/CT成像常被用作生存预后指标，但缺乏有效性。本研究探讨PRRT后PET参数变化的预后价值。方法:所有接受PRRT治疗的患者的基线和随访[68Ga]Ga-DOTA-TOC PET/CT扫描自动划定。在Cox比例风险模型中，用肿瘤总生长抑素受体表达量(TL-SSTR)和生长抑素受体表达量(SSTR-TV)作为协变量来预测到新治疗的时间。结果:20例患者中位新治疗时间为19.3个月(范围[3.8;36.2])。两种PET参数的绝对和百分比变化与新治疗时间无关。独立基线和随访SSTR-TV、随访TL-SSTR与新治疗时间之间存在显著关系。结论:自动导出的[68Ga]Ga-DOTA-TOC PET/CT参数易于获取，完成PRRT后可能具有预后价值。在基线和随访期间获得SSTR-TV或TL-SSTR参数对确定患者预后有价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊